IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYPE VEGFR-2 EXTRACELLULAR DOMAIN) (HUMAN MONOCLONAL IMC-1121B .GAMMA.-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL IMC-1121B .KAPPA.-CHAIN, DIMER
Carcinoma of Renal Pelvis
Eli Lilly and Companymonoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Carcinoma of Renal Pelvis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II H. Lee Moffitt Cancer Center and Research Institute | Phase 3 | BB |
Vinflunine Dr Anders Ullén | Phase 2 | BB |
Pembrolizumab Alliance for Clinical Trials in Oncology | Phase 3 | B |
Icrucumab Eli Lilly and Company | Phase 2 | B |
Docetaxel Eli Lilly and Company | Phase 2 | B |
View all 17 →
Same molecule, other indications
IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYPE VEGFR-2 EXTRACELLULAR DOMAIN) (HUMAN MONOCLONAL IMC-1121B .GAMMA.-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL IMC-1121B .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →